Bayer, GE, Covidien MRI Agents Carry Higher Risk: FDA

Law360, New York (November 18, 2009, 5:11 PM EST) -- A U.S. Food and Drug Administration staff review has found that certain gadolinium-based contrast agents used during MRI procedures may pose more of a risk of a fatal skin disease than other agents on the market.

The FDA’s drug safety unit determined in the review that the greatest risk of developing the disease, known as nephrogenic systemic fibrosis, was tied to GE Healthcare’s Omniscan, Bayer AG’s Magnevist and Covidien’s Optimark, according to documents posted on the agency’s Web site Tuesday.

The smallest risk was linked to...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.